Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy

A. Cancarini, C. Costagliola, R. Dell'omo, M. R. Romano, F. Morescalchi, L. Agnifili, G. Ruggeri, F. Semeraro

Research output: Contribution to journalArticle

Abstract

Aim. The aim of this study was to evaluate concentrations of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in serum, aqueous and vitreous humour of diabetic patients with proliferative retinopathy (PDR) and to verify their possible modifications induced by intravitreal injection of bevacizumab (IVB). Methods. This prospective observational study was performed on patients who underwent vitrectomy for proliferative diabetic retinopathy and macular hole or pucker. The study sample consisted of 33 patients with proliferative diabetic retinopathy and 20 non-diabetic patients with macular hole or pucker. EPO and VEGF levels in serum, aqueous and vitreous humour were measured in both groups. In diabetic patients measures were performed before and after IVB. Results. EPO and VEGF levels in aqueous and vitreous humour were markedly increased in diabetic patients with PDR as compared with those recorded in the control group (P

Original languageEnglish
Pages (from-to)305-311
Number of pages7
JournalMinerva Endocrinologica
Volume39
Issue number4
Publication statusPublished - Dec 1 2014

Keywords

  • Bevacizumab
  • Diabetes mellitus
  • Erythropoietin
  • Vascular endothelial growth factor A

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy'. Together they form a unique fingerprint.

  • Cite this

    Cancarini, A., Costagliola, C., Dell'omo, R., Romano, M. R., Morescalchi, F., Agnifili, L., Ruggeri, G., & Semeraro, F. (2014). Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy. Minerva Endocrinologica, 39(4), 305-311.